To recognize the importance of lifesaving research for the millions of people affected by cancer, the American Association for Cancer Research (AACR) established May as National Cancer Research Month.
Amgen recently kicked off a new series of oncology-driven Twitter Spaces conversations called “Science in Focus.” Jean-Charles Soria, Amgen’s Oncology Therapeutic Area Head and Senior Vice President and Angela Coxon, Head of Oncology Research, discuss Amgen’s innovative approach to early research and how Amgen is working to overcome the challenges and complexities of cancer to advance transformative medicines for people affected by this disease.
We’re studying ways to deliver more firsts in oncology in order to realize continued progress. We are looking at new targets, new mechanisms of action, new technology. Pioneering new research at the earliest stages is critical to our goal of accelerating first-in-class transformative medicines.
— Jean-Charles Soria, MD, PhD, Oncology Therapeutic Area Head
Now we have so much information to both inform the development of new approaches to cancer treatment and tailor those therapies to the appropriate patient population. One exciting immuno-oncology approach that we are focused on is T-cell engagers. Amgen’s proprietary BiTE® platform is comprised of bispecific T cell engagers, where one arm is designed to bind to a T cell and the other is designed to bind specifically to an antigen on the cancer cell. We’ve seen how this approach has been explored in hematological malignancies, and we are advancing several molecules now across several solid tumor types with high unmet need.
— Angela Coxon, Head of Oncology Research
Listen to the full conversation below, and be sure to follow Amgen Oncology on Twitter to catch our upcoming “Science in Focus” episodes.
